Literature DB >> 23674833

Predicting risk of coronary events and all-cause mortality: role of B-type natriuretic peptide above traditional risk factors and coronary artery calcium scoring in the general population: the Heinz Nixdorf Recall Study.

Kaffer Kara1, Amir A Mahabadi2, Marie H Berg3, Nils Lehmann3, Stefan Möhlenkamp2, Hagen Kälsch2, Marcus Bauer2, Susanne Moebus3, Nico Dragano3, Karl-Heinz Jöckel3, Till Neumann2, Raimund Erbel2.   

Abstract

AIMS: Several biomarkers including B-type natriuretic peptide (BNP) have been suggested to improve prediction of coronary events and all-cause mortality. Moreover, coronary artery calcium (CAC) as marker of subclinical atherosclerosis is a strong predictor for cardiovascular mortality and morbidity. We aimed to evaluate the predictive ability of BNP and CAC for all-cause mortality and coronary events above traditional cardiovascular risk factors (TRF) in the general population.
METHODS: We followed 3782 participants of the population-based Heinz Nixdorf Recall cohort study without coronary artery disease at baseline for 7.3 ± 1.3 years. Associations of BNP and CAC with incident coronary events and all-cause mortality were assessed using Cox regression, Harrell's c, and time-dependent integrated discrimination improvement (IDI(t), increase in explained variance).
RESULTS: Subjects with high BNP levels had increased frequency of coronary events and death (coronary events/mortality: 14.1/28.2% for BNP ≥100 pg/ml vs. 2.7/5.5% for BNP < 100 pg/ml, respectively). Subjects with a BNP ≥100 pg/ml had increased incidence of hard endpoints sustaining adjustment for CAC and TRF (for coronary events: hazard ratio (HR) (95% confidence interval (CI)) 3.41(1.78-6.53); for all-cause mortality: HR 3.35(2.15-5.23)). Adding BNP to TRF and CAC increased measures of predictive ability: coronary events (Harrell's c, for coronary events, 0.775-0.784, p = 0.09; for all-cause mortality 0.733-0.740, p = 0.04; and IDI(t) (95% CI), for coronary events: 2.79% (0.33-5.65%) and for all-cause mortality 1.78% (0.73-3.10%).
CONCLUSIONS: Elevated levels of BNP are associated with excess incident coronary events and all-cause mortality rates, with BNP and CAC significantly and complementary improving prediction of risk in the general population above TRF.
© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Coronary artery calcium; Heinz Nixdorf Recall Study; natriuretic peptides; prevention; risk factors

Mesh:

Substances:

Year:  2013        PMID: 23674833     DOI: 10.1177/2047487313490256

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  8 in total

1.  B-type natriuretic peptide: distribution in the general population and the association with major cardiovascular and coronary events--the Heinz Nixdorf Recall Study.

Authors:  Kaffer Kara; Amir A Mahabadi; Marie H Geisel; Nils Lehmann; Hagen Kälsch; Marcus Bauer; Till Neumann; Nico Dragano; Susanne Moebus; Stefan Möhlenkamp; Karl-Heinz Jöckel; Raimund Erbel
Journal:  Clin Res Cardiol       Date:  2013-10-15       Impact factor: 5.460

2.  Usefulness of N-terminal Pro-brain Natriuretic Peptide and Myocardial Perfusion in Asymptomatic Adults (from the Multi-Ethnic Study of Atherosclerosis).

Authors:  Adam Mitchell; Jeffrey R Misialek; Aaron R Folsom; Daniel Duprez; Alvaro Alonso; Michael Jerosch-Herold; Otto A Sanchez; Karol E Watson; Tamer Sallam; Suma H Konety
Journal:  Am J Cardiol       Date:  2015-02-18       Impact factor: 2.778

3.  Protein biomarkers identify patients unlikely to benefit from primary prevention implantable cardioverter defibrillators: findings from the Prospective Observational Study of Implantable Cardioverter Defibrillators (PROSE-ICD).

Authors:  Alan Cheng; Yiyi Zhang; Elena Blasco-Colmenares; Darshan Dalal; Barbara Butcher; Sanaz Norgard; Zayd Eldadah; Kenneth A Ellenbogen; Timm Dickfeld; David D Spragg; Joseph E Marine; Eliseo Guallar; Gordon F Tomaselli
Journal:  Circ Arrhythm Electrophysiol       Date:  2014-10-01

4.  Long-Term Hormone Replacement Therapy Is Associated with Low Coronary Artery Calcium Levels in a Cohort of Older Women: The Age, Gene/Environment Susceptibility-Reykjavik Study.

Authors:  Adalsteinn Gudmundsson; Thor Aspelund; Gunnar Sigurdsson; Tamara Harris; Lenore J Launer; Vilmundur Gudnason; Helgi Jonsson
Journal:  J Am Geriatr Soc       Date:  2016-11-11       Impact factor: 5.562

5.  Additive prognostic value of plasma N-terminal pro-brain natriuretic peptide and coronary artery calcification for cardiovascular events and mortality in asymptomatic patients with type 2 diabetes.

Authors:  Bernt Johan von Scholten; Henrik Reinhard; Tine Willum Hansen; Morten Lindhardt; Claus Leth Petersen; Niels Wiinberg; Peter Riis Hansen; Hans-Henrik Parving; Peter Karl Jacobsen; Peter Rossing
Journal:  Cardiovasc Diabetol       Date:  2015-05-21       Impact factor: 9.951

6.  Comparative analysis of high-sensitivity cardiac troponin I and T for their association with coronary computed tomography-assessed calcium scoring represented by the Agatston score.

Authors:  Jonas Rusnak; Michael Behnes; Thomas Henzler; Nadine Reckord; Nils Vogler; Mathias Meyer; Ursula Hoffmann; Michele Natale; Julia Hoffmann; Sonja Hamed; Kathrin Weidner; Siegfried Lang; Agnibh Mukherji; Holger Haubenreisser; Stefan O Schoenberg; Martin Borggrefe; Thomas Bertsch; Ibrahim Akin
Journal:  Eur J Med Res       Date:  2017-11-16       Impact factor: 2.175

7.  NT-proBNP for risk prediction of cardiovascular events and all-cause mortality: The getABI-study.

Authors:  Henrik Rudolf; Andreas Mügge; Hans J Trampisch; Hubert Scharnagl; W März; Kaffer Kara
Journal:  Int J Cardiol Heart Vasc       Date:  2020-06-05

8.  Prognostic value of NT-proBNP in patients with chronic coronary syndrome and normal left ventricular systolic function according to glucose status: a prospective cohort study.

Authors:  Hui-Hui Liu; Ye-Xuan Cao; Jing-Lu Jin; Yuan-Lin Guo; Cheng-Gang Zhu; Na-Qiong Wu; Ying Gao; Yan Zhang; Rui-Xia Xu; Qian Dong; Jian-Jun Li
Journal:  Cardiovasc Diabetol       Date:  2021-04-22       Impact factor: 9.951

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.